Apellis Pharmaceuticals IncChange company Symbol lookupSelect an option...APLS Apellis Pharmaceuticals IncPNR Pentair PLCAAL American Airlines Group IncAMD Advanced Micro Devices IncIDAI T Stamp IncVZ Verizon Communications IncCETX Cemtrex IncRNXT RenovoRx IncBNTX BioNTech SEARTW Art's Way Manufacturing Co IncGo
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. Its SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). The Company’s EMPAVELI (pegcetacoplan) is the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) is the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has an approval for the treatment of PNH in Saudi Arabia, Australia, and the United Kingdom. Systemic pegcetacoplan markets under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union and United Kingdom.
|
|
|
|
| |
APLS's position in the Biotechnology industry
| Industry Peers | INCY | XFOR | |
|---|---|---|---|
Summary | |||
| Company Profile | Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases... | Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development... Go to INCY summary | X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases... Go to XFOR summary |
| 52-Week Change | VS. INDUSTRY | -9.75% | -60.84% |
| Market Cap | VS. INDUSTRY | $15.8B | $97.2M |
| Beta | VS. INDUSTRY | 0.7 | 0.7 |
| Dividend Yield | VS. INDUSTRY | -- | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 46.53x | -- |
| Data as of | |||
Fundamentals | |||
| Total Revenue (TTM) | VS. INDUSTRY | $3.4B | $0.0 |
| Profit Margin | VS. INDUSTRY | 10.04% | -- |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -- | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | 13.67% | -- |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.